Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center

Clicks: 493
ID: 119437
2003
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Patients receiving etoposide within four weeks after diagnosis had a good prognosis as five of the seven patients survived compared to one of 13 not treated with etoposide or treated late (chi-square test for survival, P = 0.0095). The Kaplan-Meier analysis showed the 2.5-year survival of 85.7 +/- 1 …
Reference Key
s2003medicaltreatment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Imashuku S;Kuriyama K;Sakai R;Nakao Y;Masuda S;Yasuda N;Kawano F;Yakushijin K;Miyagawa A;Nakao T;Teramura T;Tabata Y;Morimoto A;Hibi S;;
Journal medical and pediatric oncology
Year 2003
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/12825212
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female male adolescent Retrospective Studies Evaluation Study histiocytosis antineoplastic agents etoposide / therapeutic use* shinsaku imashuku phytogenic / therapeutic use* pmid:12825212 doi:10.1002/mpo.10314 kikuko kuriyama shigeyoshi hibi epstein-barr virus infections / complications* non-langerhans-cell / drug therapy* non-langerhans-cell / etiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.